ipilimumab,nivolumab,durvalumab,paclitaxel,vinorelbine,carboplatin,cisplatin,gemcitabine,docetaxel,pemetrexed,pembrolizumab
bms,astrazeneca,merck
['aegean', 'cm816']
 it would be interesting to pool together data from the different trials (aegean, kn671. cm816) to get more granularity. small tumor volume (t2bn0) + pd-l1&lt;1%, the impact of multi-station or bulky disease. why 20% didn't undergo surgery, especially, in stage ii this is worrysome.
Medical Oncologist at A C Camargo Cancer Center
Sci-fi/Fantasy fan 
Love family, friends, food, travel  
The opinions and comments hereby  presented are my own.